Abstract:
A diesel fuel composition comprising a quaternary ammonium salt additive which additive is formed by the reaction of (1) a quaternising agent and (2) a compound formed by the reaction of a hydrocarbyl-substituted acylating agent and at least 1.4 molar equivalents of an amine of formula (B1) or (B2), wherein R2 and R3 are the same or different alkyl, alkenyl or aryl groups having from 1 to 22 carbon atoms; X is a bond or alkylene group having from 1 to 20 carbon atoms; n is from 0 to 20; m is from 1 to 5; and R4 is hydrogen or a C1 to C22 alkyl group.
Abstract:
The invention relates to a method of treating alcoholism and alcohol dependence in a mammal comprising administering to the mammal a therapeutically effective amount of a synergistic combination of: (i) at least one opioid antagonist, and (ii) at least one selective serotonin reuptake inhibitor. The invention also relates to compositions and kits containing the same.
Abstract:
The invention relates to a method of treating cocaine abuse or addiction in a mammal which comprises administering to the mammal an effective amount of a sigma receptor antagonist lacking or having relatively weak dopamine receptor-blocking activity, to reduce the pharmacological effects of the cocaine.
Abstract:
The invention relates to a method of treating drug abuse or addiction involving amphetamine or amphetamine-related drugs with pharmacological effects similar to amphetamine in a mammal which comprises administering to the mammal an effective amount, to reduce the pharmacological effects of the amphetamine or amphetamine-related drug, of certain piperidine sigma receptor antagonists.
Abstract:
A diesel fuel composition comprising a quaternary ammonium salt additive which additive is formed by the reaction of (1) a quaternising agent and (2) a compound formed by the reaction of a hydrocarbyl-substituted acylating agent and at least 1.4 molar equivalents of an amine of formula (B1) or (B2), wherein R2 and R3 are the same or different alkyl, alkenyl or aryl groups having from 1 to 22 carbon atoms; X is a bond or alkylene group having from 1 to 20 carbon atoms; n is from 0 to 20; m is from 1 to 5; and R4 is hydrogen or a C1 to C22 alkyl group.
Abstract:
The present invention provides a composition comprising: i) at least one compound of formula (I): wherein R1 and R2 are independently selected from a group consisting of hydrogen, unsubstituted or substituted C1-19 hydrocarbyl or a group of formula (II): wherein Q is a bond or an unsubstituted or substituted hydrocarbyl group; wherein R3 is selected from a group consisting of hydrogen and unsubstituted or substituted C1-18 hydrocarbyl; wherein the R1—C—R2 backbone is from 5 to 20 atoms in length; wherein each A and B is independently an unsubstituted or substituted unsaturated cyclic hydrocarbyl group; and wherein n is an integer from 0 to 10; and ii) a diluent or carrier; wherein the compound(s) of formula (I) is present in an amount sufficient to provide, at −30° C., at least 1 wt % of iron, based on the weight of the composition.
Abstract:
The present invention provides a composition comprising: i) at least one compound of formula (I): wherein R1 and R2 are independently selected from a group consisting of hydrogen, unsubstituted or substituted C1-19 hydrocarbyl or a group of formula (II): wherein Q is a bond or an unsubstituted or substituted hydrocarbyl group; wherein R3 is selected from a group consisting of hydrogen and unsubstituted or substituted C1-18 hydrocarbyl; wherein the R1—C—R2 backbone is from 5 to 20 atoms in length; wherein each A and B is independently an unsubstituted or substituted unsaturated cyclic hydrocarbyl group; and wherein n is an integer from 0 to 10; and ii) a diluent or carrier; wherein the compound(s) of formula (I) is present in an amount sufficient to provide, at −30° C., at least 1 wt % of iron, based on the weight of the composition.
Abstract:
The invention relates to a method of treating alcoholism and alcohol dependence in a mammal comprising administering to the mammal a therapeutically effective amount of a synergistic combination of: (i) at least one opioid antagonist, and (ii) at least one selective serotonin reuptake inhibitor. The invention also relates to compositions and kits containing the same.